CER Daily Newsfeed

Institute for Clinical and Economic Review Publishes Protocol for Annual Launch Price and Access Report

(5/4, ICER Press Release) “The Institute for Clinical and Economic Review (ICER) posted a Protocol today outlining how it will conduct its second annual analysis titled the ‘Launch Price and Access Report,’ which will examine launch prices and patient access for new FDA-approved treatments. This protocol was developed with input from a multi-stakeholder working group* consisting of patient and consumer advocates, clinicians, policy experts, payers, and life science companies.” Full

Major Milestone under the EU HTA Regulation: First Joint clinical Assessment of Benefit Complete.

(5/4, National Centre for Pharmacoeconomics, Ireland Press Release) “...‘After many years of preparation through EUnetHTA joint actions, it is wonderful to see joint EU HTA become a reality with the endorsement of the first JCA...The assessment also provided an important opportunity to apply, in practice, the methodological guidance developed over several years under the HTACG and EUnetHTA, ensuring a high-quality final report. The close collaboration with our co-assessors IQWiG, whose exceptional commitment to excellence ensured the highest quality in our joint work, and with whom we thoroughly enjoyed working contributed to the success of this first JCA. We look forward to continuing this spirit of open and constructive collaboration with other HTA bodies in future joint assessments’ said Roisin Adams, Head of HTA Strategy, NCPE, Ireland.” Full